0.8399
price down icon9.97%   -0.093
 
loading
Precedente Chiudi:
$0.9329
Aprire:
$0.89
Volume 24 ore:
490.07K
Relative Volume:
0.06
Capitalizzazione di mercato:
$11.04M
Reddito:
-
Utile/perdita netta:
$-7.51M
Rapporto P/E:
-0.6363
EPS:
-1.32
Flusso di cassa netto:
$-8.02M
1 W Prestazione:
-18.46%
1M Prestazione:
-32.27%
6M Prestazione:
+1.68%
1 anno Prestazione:
-41.27%
Intervallo 1D:
Value
$0.814
$0.90
Intervallo di 1 settimana:
Value
$0.814
$1.05
Portata 52W:
Value
$0.58
$3.80

Hoth Therapeutics Inc Stock (HOTH) Company Profile

Name
Nome
Hoth Therapeutics Inc
Name
Telefono
(646)756-2997
Name
Indirizzo
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Name
Dipendente
3
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-11
Name
Ultimi documenti SEC
Name
HOTH's Discussions on Twitter

Confronta HOTH con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
HOTH
Hoth Therapeutics Inc
0.8399 11.04M 0 -7.51M -8.02M -1.32
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2019-10-15 Iniziato The Benchmark Company Speculative Buy

Hoth Therapeutics Inc Borsa (HOTH) Ultime notizie

pulisher
Apr 02, 2025

Hoth Therapeutics reports Alzheimer’s drug candidate success By Investing.com - Investing.com South Africa

Apr 02, 2025
pulisher
Apr 02, 2025

Hoth Flat on Hookup with Washington Univ. - Baystreet.ca

Apr 02, 2025
pulisher
Apr 02, 2025

Hoth Therapeutics reports Alzheimer’s drug candidate success - Investing.com India

Apr 02, 2025
pulisher
Apr 02, 2025

Hoth Therapeutics Plans To Advance HT-ALZ Into Clinical Development - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

Breakthrough: New Alzheimer's Drug Cuts Key Brain Marker by 15%University Study Reveals - Stock Titan

Apr 02, 2025
pulisher
Apr 02, 2025

Revolutionary Alzheimer's Treatment Cuts Brain Amyloid by 15% in Just 20 Hours - Stock Titan

Apr 02, 2025
pulisher
Apr 01, 2025

Hoth Therapeutics (NASDAQ:HOTH) Receives “Buy” Rating from D. Boral Capital - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

Hoth Therapeutics receives USPTO filing receipt for HT-001 patent application - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

New Patent Filing Strengthens Hoth's Cancer Treatment IP PortfolioKey Details - Stock Titan

Mar 31, 2025
pulisher
Mar 28, 2025

Hoth Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

Hoth Therapeutics Inc. (HOTH) reports earnings - Quartz

Mar 28, 2025
pulisher
Mar 28, 2025

Hoth Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 28, 2025
pulisher
Mar 26, 2025

Hoth Therapeutics enhances patent claims, begins toxicity study By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Hoth Therapeutics enhances patent claims, begins toxicity study - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

Major Progress: Hoth's Cancer-Fighting Drug Secures Patent Protection and Launches Critical Safety Study - Stock Titan

Mar 26, 2025
pulisher
Mar 24, 2025

Hoth Therapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView

Mar 24, 2025
pulisher
Mar 20, 2025

Hoth Therapeutics (HOTH) Projected to Post Earnings on Thursday - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Balance Sheet Breakdown: Hoth Therapeutics Inc (HOTH)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex

Mar 19, 2025
pulisher
Mar 19, 2025

Hoth Therapeutics announces ‘positive’ results from study of HT-KIT - Yahoo Finance

Mar 19, 2025
pulisher
Mar 19, 2025

Hoth reports progress in GIST treatment with HT-KIT By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

Hoth reports progress in GIST treatment with HT-KIT - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment - PR Newswire

Mar 18, 2025
pulisher
Mar 18, 2025

Revolutionary 24-Hour Cancer Treatment Success: Hoth's HT-KIT Destroys GIST Tumors in Breakthrough Study - Stock Titan

Mar 18, 2025
pulisher
Mar 17, 2025

Short Interest in Hoth Therapeutics, Inc. (NASDAQ:HOTH) Decreases By 24.8% - Defense World

Mar 17, 2025
pulisher
Mar 10, 2025

Hoth Therapeutics to submit HT-001 expanded access application By Investing.com - Investing.com Australia

Mar 10, 2025
pulisher
Mar 10, 2025

Hoth Therapeutics Announces Plans To Submit Expanded Access Application For Ht-001 To Support Cancer Patients In Need - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Hoth Dips on Drug Application - Baystreet.ca

Mar 10, 2025
pulisher
Mar 10, 2025

Hoth Therapeutics to submit Expanded Access application for HT-001 - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Hoth Therapeutics to submit HT-001 expanded access application - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need - PR Newswire

Mar 10, 2025
pulisher
Mar 05, 2025

Hoth Therapeutics reports HT-001 cream success in skin toxicity By Investing.com - Investing.com South Africa

Mar 05, 2025
pulisher
Mar 05, 2025

Hoth Therapeutics reports HT-001 cream success in skin toxicity - Investing.com India

Mar 05, 2025
pulisher
Mar 05, 2025

Hoth Therapeutics reports ‘promising’ results for HT-001 therapeutic candidate - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting - PR Newswire

Mar 05, 2025
pulisher
Mar 05, 2025

Hoth Therapeutics’ (HOTH) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Hoth Therapeutics Announces Positive Findings On GDNF's Potential As A Game-Changer In Obesity Treatment And Reduced Fatty Liver Disease - MarketScreener

Mar 04, 2025
pulisher
Mar 04, 2025

Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease - PR Newswire

Mar 04, 2025
pulisher
Mar 04, 2025

Financial Contrast: Emmaus Life Sciences (OTCMKTS:EMMA) and Hoth Therapeutics (NASDAQ:HOTH) - Defense World

Mar 04, 2025
pulisher
Feb 17, 2025

HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal - MSN

Feb 17, 2025
pulisher
Feb 12, 2025

Hoth Therapeutics (NASDAQ:HOTH) Given Buy Rating at D. Boral Capital - Defense World

Feb 12, 2025
pulisher
Feb 10, 2025

Hoth Therapeutics to Present at the LD Micro Main Event (XII) - ACCESS Newswire

Feb 10, 2025
pulisher
Feb 10, 2025

What to expect from HOTH’s earnings report this quarter? - US Post News

Feb 10, 2025
pulisher
Feb 10, 2025

Hoth Therapeutics, OnTargetx R&D Partner to Advance Research for Cancer Therapeutic - Contract Pharma

Feb 10, 2025
pulisher
Feb 10, 2025

HOTH's Cancer Breakthrough: Strategic Alliance Accelerates Novel HT-KIT Therapeutic Research - StockTitan

Feb 10, 2025
pulisher
Feb 08, 2025

Hoth Therapeutics expands at-the-market offering by $5 million - Investing.com Australia

Feb 08, 2025
pulisher
Jan 27, 2025

Research Analysts Set Expectations for HOTH FY2024 Earnings - Defense World

Jan 27, 2025

Hoth Therapeutics Inc Azioni (HOTH) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Capitalizzazione:     |  Volume (24 ore):